FLT3 Mutation Analysis, Varies
Use
The FLT3 Mutation Analysis test is used as a prognostic tool for some patients with acute myeloid leukemia (AML). Variants in the FLT3 gene have been found in hematopoietic neoplasms, particularly common in adult AML. These mutations include internal tandem duplication (ITD) and point alterations in the D835 codon, which serve as prognostic indicators. The identification of these variants is clinically significant due to the potential use of FLT3-inhibitory drugs as therapeutic agents.
Special Instructions
This test should not be used to monitor residual disease following treatment. The specimen must arrive within 7 days of collection. The test requires pertinent clinical history, clinical or morphologic suspicion, date and time of collection, and specimen source information.
Limitations
The test is not designed for monitoring residual disease. The sensitivity of the test is less than methods designed for residual disease testing, and there are reports of FLT3 variants being lost or gained in neoplastic cells after treatment. Specimens with gross hemolysis, bone marrow biopsies, slides, paraffin shavings, or that are moderately to severely clotted may be rejected.
New York Approved
Methodology
PCR-based
Biomarkers
LOINC Codes
- 79210-1
- 31208-2
- 34574-4
- 79210-1
Result Turnaround Time
3-6 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA) or yellow top (ACD)
Collection Instructions
Invert several times to mix blood. Send specimen in original tube. Do not aliquot. Label specimen as whole blood.
Causes for Rejection
Gross hemolysis, Bone marrow biopsies, Slides, Paraffin shavings, Moderately to severely clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |